• Home
  • NEW DAY MEDICINE
  • 9 (47) 2022
  • 38 — 9 (47) 2022 — Sh.K. Yusupova, SIGNIFICANCE OF N-TERMINAL SODIUM-URETIC PEPTIDE IN THE DIAGNOSIS OF CHRONIC HEART FAILURE

38 — 9 (47) 2022 — Sh.K. Yusupova, SIGNIFICANCE OF N-TERMINAL SODIUM-URETIC PEPTIDE IN THE DIAGNOSIS OF CHRONIC HEART FAILURE

SIGNIFICANCE OF N-TERMINAL SODIUM-URETIC PEPTIDE IN THE DIAGNOSIS OF CHRONIC HEART FAILURE

Sh.K. Yusupova,Andijan State Medical Institute

Resume

The aim of the study was to study the significance of the N–terminal sodium-uretic peptide in the diagnosis of chronic heart failure

Material and methods of research. 185 patients were identified and selected as the object of the study based on the materials of their treatment in the medical and preventive institutions of Andijan from 30 years and older.

The patients were divided into 3 groups:

group 1 – patients with type 2 diabetes mellitus (DM 2) + chronic heart failure (CHF) – 65 patients,

Group 2 is patients with  DM 2  without CHF – 60 patients,

Group 3 – these are patients with CHF without type 2 diabetes – 60 patients

Results. In all groups, the average values of NTproBNP were significantly higher than the reference values. In groups 1 and 3, the average values of NTproBNP were significantly higher compared to those of the group of patients with type 2 diabetes without CHF (P<0.001). The highest levels of NTproBNP were found in patients with  DM 2 +CHF.

Conclusions. Correlation analysis showed the presence of a direct correlation of average strength between NTproBNP indicators and the age of patients suffering from DM2 in combination with CHF, a weakly positive correlation between NTproBNP and BMI, an inverse correlation of average strength between the level of NTproBNP and LV LV, a negative and average strength relationship between the level of NTproBNP and VFR, and also revealed a significant relationship between the level of NTproBNP and glycated hemoglobin.

Our results confirm the literature data on the high diagnostic significance of NTproBNP in the diagnosis of CHF.

Keywords: type 2 diabetes mellitus, chronic heart failure, NTproBNP

First page

231

Last page

237

For citation: Sh.K. Yusupova, SIGNIFICANCE OF N-TERMINAL SODIUM-URETIC PEPTIDE IN THE DIAGNOSIS OF CHRONIC HEART FAILURE //New Day in Medicine 9 (47)2022 231-237 https://l.clck.bar/e04a9

LIST OF REFERENCES:

  1. Oremus M. et al. A systematic review of BNP and NT-proBNP in the management of heart failure: overview and methods. // Heart Fail. Rev. 19, 413– 419 (2014).
  2. Tang W.H.W. B-type natriuretic peptide: a critical review. Congest. // Heart Fail. 13, 48– 52 (2007)
  3. Ponikowski P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. // Eur. Heart J. 37, 2129– 2200 (2016).
  4. Yancy C.W. et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. // Circulation 128, 1810– 1852 (2013).
  5. Balion C, Santaguida PL, Hill S, et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. // Evid Rep Technol Assess 2006;(142):1-147.
  6. Geng Z., Huang, L., Song, M. & Song, Y. N-terminal pro-brain natriuretic peptide and cardiovascular or all-cause mortality in the general population: A meta-analysis. // Sci. Rep. 7, 41504 (2017).
  7. Van Veldhuisen D.J. et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. // J. Am. Coll. Cardiol. 61, 1498– 1506 (2013).
  8. Lam C.S.P. et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study. // Eur. Heart. J. 39, 1770– 1780 (2018).
  9. Gheorghiade M. et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. // JAMA 314, 2251– 2262 (2015).
  10. Pieske B. et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. // Eur. Heart J. 38, 1119– 1127 (2017).
  11. Solomon, S.D. et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. // Lancet 380, 1387– 1395 (2012).

file

download